That is the case in some neurodegenerative diseases or in conditions where degradation of a protein could have major impact than its enzymatic inhibition, as in the case of IRAK4 targeting in autoimmune diseases [81, 82]. Here, IRAK4 is linked to neurodegenerative disease.